Replies to post #795711 on NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

The October 30, 2025 Form 8-K already fulfilled the SEC’s immediate requirement for disclosure under Item 1.01. It reported that Northwest Biotherapeutics closed the Advent BioServices acquisition, listed Advent as the counterparty, confirmed that Advent became a wholly owned subsidiary, detailed the consideration of £1.4 million plus net accounts payable over two years, and noted that no new shares were issued. It also disclosed that 19 million shares and options previously issued to Advent reverted back to the company. That is the exact purpose of a Form 8-K—to disclose a material definitive agreement within four business days of closing.

The part that’s being claimed as missing actually falls under a different SEC rule, Regulation S-K Item 404, which governs related-party transactions. That rule requires companies to disclose the related person’s identity, relationship, amounts involved, and how the board handled approval, recusal, and fairness review. Those governance details do not appear in the 8-K because they are reported later in the company’s annual report (Form 10-K) or proxy statement (DEF 14A).

NWBO’s fiscal year ends December 31, 2025. The Form 10-K is due about 90 days after year-end, around March 31, 2026. If the company provides the disclosure in its proxy statement instead, that must be filed within 120 days after year-end, around April 30, 2026. Either way, the related-party section under Item 404 will appear by that timeframe, which is the legally required window.

So the 8-K handled the immediate disclosure exactly as required. The governance and conflict-of-interest details follow automatically in the next 10-K or proxy under SEC timing rules. There is nothing omitted or noncompliant in the sequence.

[biosectinvestor]

Your summary of the requirements misrepresents both the law and the facts. Under Item 404(a) of Regulation S-K, related-party transactions over $120,000 require disclosure, not shareholder approval. The rule covers the most recent fiscal year, not three years, and mandates identification of the related person, the relationship, the amount, and the material interest — nothing more.

Board or shareholder approval is not required by the SEC. Those safeguards come from company governance policies. In Northwest Biotherapeutics’ case, its Related-Party Transaction Policy goes further than the SEC baseline by requiring advance independent-committee review and approval, with any conflicted director recused.

Just as important, the related-party connection — including Advent and Toucan — has been consistently disclosed for years in NWBO’s SEC filings. The relationship has never been hidden.

In short, NWBO has met both the letter and the spirit of the disclosure rules, and the suggestion that these relationships were undisclosed or unapproved is incorrect.